Celyad Oncology (Celyad Oncology) 3-Year EPS without NRI Growth Rate : 27.10% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology 3-Year EPS without NRI Growth Rate?

Celyad Oncology's EPS without NRI for the three months ended in Jun. 2023 was $0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 27.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Celyad Oncology was 27.10% per year. The lowest was -24.90% per year. And the median was 6.10% per year.

Competitive Comparison of Celyad Oncology's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Celyad Oncology's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's 3-Year EPS without NRI Growth Rate falls into.

Celyad Oncology 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Celyad Oncology (OTCPK:CYADY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Celyad Oncology 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.